Media
Press Release
13
2023.02
Completion Of The First Batch Of Subject Enrollmentfor The Phase I Clinical Trial Of The Company’s Novel Adjuvanted Recombinant Shingles Vaccine REC610
23
2022.12
Superior Neutralizing Antibody Titer Levels Against Omicron BF.7 And BA.2.75 Of The Company’s Two-Component Recombinant COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine
19
2022.12
Clinical Trial Approval For The Company’s Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines
14
2022.12
Superior Results Of The Comparative Study Of The Company’S Recombinant Two-Component Covid-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine
Publications
2023.03.06
Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2
Download
2022.05.11
The preliminary safety and immunogenicity results of a randomized, double-blind, placebo-controlled Phase I trial for a recombinant two-component subunit SARS-CoV-2 vaccine ReCOV
2022.02.12
Lyophilized mRNA-lipid nanoparticles vaccine with long-term stability and high antigenicity against SARS-CoV-2
2021.11.09
A trimeric NTD and RBD SARS-CoV-2 subunit vaccine induced protective immunity in CAG-hACE2 transgenic mice and rhesus macaques